Clinical trials in irritable Bowel syndrome: A review

Reviews on Recent Clinical Trials

Volumn 8, Issue 1, 2013, Pages 9-22

  Ervin, Claire M ^a   Mangel, Allen W ^a  

^a RTI HEALTH SOLUTIONS   (United States)

Author keywords

Abdominal pain; Bowel functions; Constipation predominant; Diarrhea predominant; Irritable bowel syndrome

Indexed keywords

ALOSETRON; AMITRIPTYLINE; ASIMADOLINE; AZD7371; CROFELEMER; DNK333; LINACLOTIDE; LUBIPROSTONE; LX1031; OXYGENASE INHIBITOR; PHLOROGLUCINOL; PLACEBO; RECEPTOR BLOCKING AGENT; RENZAPRIDE; RIFAXIMIN; SEROTONIN 1A ANTAGONIST; TEGASEROD; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL TRIAL (TOPIC); HUMAN; IRRITABLE COLON; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PILL; PRIORITY JOURNAL; PUBLICATION; SYSTEMATIC REVIEW;

ALPROSTADIL; BENZAMIDES; BICYCLO COMPOUNDS, HETEROCYCLIC; BIPHENYL COMPOUNDS; CARBOLINES; DOSE-RESPONSE RELATIONSHIP, DRUG; GASTROINTESTINAL AGENTS; HUMANS; INDOLES; IRRITABLE BOWEL SYNDROME; PEPTIDES; PHENYLALANINE; PHLOROGLUCINOL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RIFAMYCINS;

EID: 84874856941     PISSN: 15748871     EISSN: 18761038     Source Type: Journal    
DOI: 10.2174/1574887111308010003     Document Type: Article

References (52)

1. Everhart JE, Renault PF. Irritable bowel syndrome in office-based practice in the United States. Gastroenterology 1991; 100: 998-1005.
2. Russo MW, Gaynes BN, Drossman DA. A national survey of practice patterns of gastroenterologists with comparison to the past two decades. J Clin Gastroenterol 1999; 29: 339-43.
3. Andrews EB, Eaton SC, Hollis KA, Hopkins JS, Ameen V, Hamm LR, et al. Prevalence and demographics of irritable bowel syndrome: results from a large web-based survey. Aliment Pharmacol Ther 2005; 22: 935-42.
4. Drossman DA, Li Z, Andruzzi E, Temple RD, Talley NJ, Thompson WG, et al. US householder survey of functional gastrointestinal disorders: prevalence, sociodemography, and health impact. Dig Dis Sci 1993; 38: 1569-80.
5. Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA technical review on irritable bowel syndrome. Gastroenterology 2002; 123: 2108-31.
6. Manning AP, Thompson WG, Heaton KW, Morris AF. Towards a positive diagnosis of the irritable bowel. Br Med J 1978; 2: 653-54.
7. Hahn BA, Yan S, Strassels S. Impact of irritable bowel syndrome on quality of life and resource use in the United States and United Kingdom. Digestion 1999; 60: 77-81.
8. Patrick DL, Drossman DA, Frederick IO, Dicesare J, Puder KL. Quality of life in persons with irritable bowel syndrome: development and validation of a new measure. Dig Dis Sci 1998; 43: 400-11.
9. Gralnek IM, Hays RD, Kilbourne A, Naliboff B, Mayer EA. The imact of irritable bowel syndrome on health-related quality of life. Gastroenterology 2000; 119: 654-60.
10. Whitehead WE, Burnett CK, Cook EW, Taub E. Impact of irritable bowel syndrome on quality of life. Dig Dis Sci 1996; 41: 2248-53.
11. Koloski N, Talley NJ, Boyce PM. The impact of functional gastrointestinal disorders on quality of life. Am J Gastoenterol 2000; 95: 67-71.
12. Irvine EJ, Ferrazzi S, Pare P, Thompson WG, Rance L. Health-related quality of life in functional GI disorders: focus on constipation and resource utilization. Am J Gastroenterol 2002; 97: 1986-93.
13. Watson ME, Lacey L, Kong S, Northcutt AR, McSorley D, Hahn B, et al. Alosetron improves quality of life in women with diarrheapredominant irritable bowel syndrome. Am J Gastroenterol 2001; 96: 455-9.
14. Inadomi JM, Fennerty MB, Bjorkman D. Systematic review: the economic impact of irritable bowel syndrome. Aliment Pharmacol Ther 2003; 18: 671-82.
15. Wells NEJ, Hahn BA, Whorwell PJ. Clinical economics review: irritable bowel syndrome. Aliment Pharmacol Ther 1997; 11: 1019-30.
16. Talley NJ, Gabriel SE, Harmsen WS, Zinsmeister AR, Evans RW. Medical costs in community subjects with irritable bowel syndrome. Gastroenterology 1995; 109: 1736-41.
17. Hungin P, Barghout V, Kahler K. The impact of IBS on absenteeism and work productivity: United States and eight European countries. Am J Gastroenterol 2003; 98(Suppl): S227.
18. Hasler WL, Schoenfeld P. Systematic review: abdominal and pelvic surgery in participants with irritable bowel syndrome. Aliment Pharmacol Ther 2003; 997-1005.
19. Hungin APS, Whorwell PJ, Tack J, Mearin F. The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects. Aliment Pharmacol Ther 2003; 17: 643-50.
20. Williams RE, Black CL, Kim HY, Andrews EB, Mangel AW, Buda JJ, et al. Determinants of health-care seeking behavior among subjects with irritable bowel syndrome. Aliment Pharmacol Ther 2006; 23: 1667-75.
21. Mangel AW, Fehnel SE, Earnshaw SR, Mangel TP. Pathways for the development of drugs to treat irritable bowel syndrome: from molecule identification through approval. In: Irritable Bowel Syndrome. New York, Nova Science Publishers. 2009 pp. 1-15.
22. Mangel AW, Northcutt AR. Review article: safety and efficacy of alosetron, a 5HT3 receptor antagonist, in female irritable bowel syndrome patients. Aliment Pharmacol Ther 1999; 13(Suppl 2): 77-82.
23. US Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Guidance for Industry-Irritable bowel Syndrome-Clinical Evaluation of Drugs for Treatment. Food and Drug Administration. [cited: 27 July 2012]. Silver Spring (MD): Food and Drug Administration. May 2012. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidance s/UCM205269.pdf.
24. Mangel AW. The FDA and IBS drug development. Am J Gastroenterol 2009; 104: 3106.
25. Mangel AW, Wang J, Sherrill E, Gnanasakthy A, Ervin C, Fehnel S. Urgency as an endpoint in irritable bowel syndrome. Gastroenterology Research 2011; 4: 9-12.
26. Bardhan KD, Bodeman G, Geldof H, Schütz E, Heath A, Mills JG, et al. A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2000; 14: 23-34.
27. Lembo T, Wright RA, Bagby B, Decker C, Gordon S, Jhingran P, et al. Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2001; 96: 2662-70.
28. Lembo AJ, Olden KW, Ameen VZ, Gordon SL, Heath AT, Carter EG. Effect of alosetron on bowel urgency and global symptoms in women with severe diarrhea-predominant irritable bowel syndrome: analysis of two controlled trials. Clin Gastroenterol Hepatol 2004; 2: 675-82.
29. Chey WD, Chey WY, Heath AT, et al. Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2004; 99: 2195-203.
30. Camilleri M, Chey WY, Mayer EA, et al. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Arch Intern Med 2001; 161: 1733-40.
31. Chang L, Ameen VZ, Dukes GE, McSorley DJ, Carter EG, Mayer EA. A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS. Am J Gastroenterol 2005; 100: 115-23.
32. Olden K, DeGarmo RG, Jhingran P, et al. Patient satisfaction with alosetron for the treatment of women with diarrhea-predominant ir ritable bowel syndrome. Am J Gastroenterol 2002; 97: 3139-46.
33. Krause R, Ameen V, Gordon SH, West M, Heath AT, Perschy Tet al. A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS. Am J Gastroenterol 2007; 102: 1709-19.
34. Mangel AW, Bornstein JD, Hamm LR, Buda J, Wang J, Irish W, et al. Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome. Aliment Pharmacol Ther 2008; 28: 239-49.
35. Szarka LA, Camilleri M, Burton D, Fox JC, McKinzie S, Stanislav T, et al. Efficacy of on-demand asimadoline, a peripheral K-opioid agonist, in females with irritable bowel syndrome. Clin Gastroenterol Hepatol 2007; 5: 1268-75.
36. Pimentel M, Park S, Mirocha J, Kane SV, Kong Y. The effect of a nonabsorbed oral antiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med 2006; 145: 557-63.
37. Pimentel M, Lembo A, Chey WD, Zakko S, Ringel Y, Yu J, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Eng J Med 2011; 364: 22-32.
38. Brown PM, Drossman DA, Wood AJ, et al. The tryptophan hydroxylase inhibitor LX1031 shows clinical benefit in patients with nonconstipating irritable bowel irritable bowel syndrome. Gastroenterology 2011; 141: 507-16.
39. Vahedi H, Merat S, Momtahen S, Kazzazi AS, Ghaffari N, Olfati G, et al. Clinical trial: the effect of amitriptyline in patients with diarrhea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2008; 27: 678-84.
40. Mangel AW, Chaturvedi P. Evaluation of crofelemer in the treatment of diarrhea-predomiant irritable bowel syndrome patients. Digestion 2008; 78: 180-186.
41. Zakko S, Barton G, Weber E, Dunger-Baldauf C, Ruhl A. Randomised clinical trial: the clinical effects of a novel neurokinin receptor antagonist, DNK333, in women with diarrhea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2011; 33: 1311-21.
42. Johnston JM, Kurtz CB, Macdougall JE, Lavins BJ, Currie MG, Fitch DA, et al. Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation. Gastorenterology 2010; 139: 1877-86.
43. Johanson JF, Drossman DA, Panas R, Wahle A, Ueno R. Clinical trial: phase 2 study of lubiprosotone for irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2008; 27: 685-96.
44. Drossman DA, Chey WD, Johanson JF, Fass R, Scott C, Panas R, et al. Clinical trial: lubiprostone in patients with constipationassociated irritable bowel syndrome-results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther 2009; 29: 329-41.
45. Novick J, Miner P, Krause R, et al. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2002; 16: 1877-88.
46. Kellow J, Lee Oy, Chang FY. An Asia-Pacific, double blind, placebo controlled, randomized study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome. Gut 2003; 62: 671-6.
47. Nyhlin H, Bang C, Elsborg L, et al. A double-blind, placebocontrolled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome. Scand J Gastroenterol 2004; 39: 119-26.
48. Chey WD, Pare P, Viegas A, Ligozio G, Shetzline MA. Tegaserod for female patients suffering from IBS with mixed bowel habits or constipation: a randomized controlled trial. Am J Gastroentero. l 2008; 103: 1217-25.
49. George AM, Meyers NL, RI Hickling. Clinical trial: renapride therapy for constipation-predominant irritable bowel syndromemulticentre, randomized, placebo-controlled, double-blind study in primary healthcare setting. Aliment Pharmacol Ther 2008; 27: 830-37.
50. Spiller RC, Meyers NL, Hickling RI. Identification of patients with non-D, non-C irritable bowel syndrome and treatment with renzapride: an exploratory, multicenter, randomized, double-blind, placebo-controlled clinical trial. Dig Dis Sci 2008; 53: 3191-200.
51. Drossman DA, Danilewitz M, Naesdal J, Hwang C, Adler J, Silberg DG. Randomized, double-blind, placebo-controlled trial of the 5HT1A receptor antagonist AZD7371 tartrate monohydrate (robalzotan tartrate monohydrate) in patients with irritable bowel syndrome. Am J Gastroenterol 2008; 103: 2562-69.
52. Chassany O, Bonaz B, Bruley des Varannes S, Bueno L, et al. Acute exacerbation of pain in irritable bowel syndrome: efficacy of phloroglucinol/trimethylphloroglucinol-a randomized, doubleblind, placebo-controlled study. Aliment Pharmacol Ther 2007; 25: 1115-23.